* To replay the media content and watch again, please refresh your screen

In this first interactive patient case video from BREAST CANCER CONNECT expert Dr Elisa Agostinetto,  you will explore the complexities of a patient facing ER+/HER2- de novo metastatic breast cancer.

As you journey through the entire diagnostic and treatment process, you'll interact and engage with valuable information, challenging questions and clickable resources along the way.

In the second interactive patient case, Prof. Valentina Guarneri presents a patient with ER+/HER2- metastatic breast cancer.

Clinical Takeaways

  • Assessing tumour characteristics, including prevalent mutations like ESR1 and PIK3CA, can significantly influence and guide treatment choices in patients with ER+/HER2- metastatic breast cancer

  • Liquid biopsy, specifically blood-based ctDNA analysis, is the preferred method for detecting ESR1 mutations due to its heightened sensitivity and the avoidance of repeat biopsies at metastatic sites

  • Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2-  metastatic breast cancer harbouring an ESR1 mutation

  • Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice

Dr Elisa Agostinetto is a medical oncologist and leading researcher in the field of breast cancer. She received her medical degree in Italy, at University of Udine. She completed her training in medical oncology in Milan, Italy, and afterwards she moved to Brussels, Belgium, where she is currently pursuing an advanced research fellowship at Institut Jules Bordet - Université Libre de Bruxelles.

Dr Elisa Agostinetto has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Sandoz, AstraZeneca; support for conference attendence from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, AstraZeneca and a research grant to her institution from Gilead.

Programme summary
  • clock Duration 15 MIN
  • clock Language(s) flag
Other episodes in this series
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 1

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 1

An interactive patient case video series from breast cancer specialists

Current Episode
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Share this programme
This educational programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Medical Educational Grant from Menarini Stemline Oncology.

Meet the experts

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

2

of 3

episode
Oncology 
Câncer de Pulmão: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 2 da série de podcasts em vídeo de 3 partes

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.